Hypothalamic regulation of energy homeostasis

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 16, Issue 4, 2002, Pages 623-637

  Sainsbury, Amanda ^a   Cooney, Gregory J ^a   Herzog, Herbert ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

AgRP; CART; Energy expenditure; Energy intake; Hormone output; Hypothalamus; NPY; MSH

Indexed keywords

AGOUTI RELATED PROTEIN; ALPHA INTERMEDIN; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; GHRELIN; GLUCOCORTICOID; HORMONE; INSULIN; LEPTIN; LIPID; MELANOCORTIN 4 RECEPTOR; NEUROPEPTIDE; NEUROPEPTIDE Y; ANOREXIGENIC AGENT; APPETITE STIMULANT; MELANOCORTIN;

ANOREXIA; APPETITE; ENDOCRINE FUNCTION; ENERGY BALANCE; ENERGY CONSUMPTION; ENERGY EXPENDITURE; FEEDING BEHAVIOR; FOOD INTAKE; GENE DELETION; GENETIC AND FAMILIAL DISORDERS; HOMEOSTASIS; HORMONE RELEASE; HUMAN; HYPOTHALAMUS FUNCTION; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LIPID METABOLISM; NERVE CELL; NONHUMAN; OBESITY; PEPTIDE SYNTHESIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ADRENAL CORTEX; BRAIN REGION; BRAIN STEM; GENETIC MODEL; HYPOTHALAMUS; INSULIN BLOOD LEVEL; KNOCKOUT GENE; METABOLIC RATE; PHYSICAL ACTIVITY;

EID: 12244265510     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1053/beem.2002.0230     Document Type: Review

References (104)

1. Perusse L & Bouchard C. Gene-diet-interactions in obesity. American Journal of Clinical Nutrition 2000; 72: 1285S-1290S.
2. Hill JO & Peters JC. Environmental contributions to the obesity epidemic. Science 1998; 280: 1371-1374.
3. Corbett SW, Kaufman LN & Keesey RE. Thermogenesis after lateral hypothalamic lesions: Contributions of brown adipose tissue. American Journal of Physiology 1988; 255: E708-E715.
4. Williams G, Bing C, Cai XJ et al. The hypothalamus and the control of energy homeostasis: Different circuits, different purposes. Physiology and Behavior 2001; 74: 683-701.
5. Sclafani A. Neural pathways involved in the ventromedial hypothalamic lesion syndrome in the rat. Journal of Comparative and Physiological Psychology 1971; 77: 70-96.
6. Debons AF, Siclari E, Das KC et al. Gold thioglucose-induced hypothalamic damage, hyperphagia, and obesity: Dependence on the adrenal gland. Endocrinology 1982; 110: 2024-2029.
7. Penicaud L, Rohner-Jeanrenaud F & Jeanrenaud B. In vivo metabolic changes as studied longitudinally after ventromedial hypothalamic lesions. American Journal of Physiology 1986; 250: E662-E668.
8. Sakaguchi T, Bray GA & Eddlestone G. Sympathetic activity following paraventricular or ventromedial hypothalamic lesions in rats. Brain Research Bulletin 1988; 20: 461-465.
9. Jordaan GP, Roberts MC & Emsley RA. Serotonergic agents in the treatment of hypothalamic obesity syndrome: A case report. International Journal of Eating Disorders 1996; 20: 111-113.
10. Lustig RH, Rose SR, Burghen GA et al. Hypothalamic obesity caused by cranial insult in children: Altered glucose and insulin dynamics and reversal by a somatostatin agonist. Journal of Pediatrics 1999; 135: 162-168.
11. Friedman JM & Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-770.
12. Wilding JPH, Gilbey SG, Bailey CJ et al. Increased neuropeptide-Y messenger and decreased neurotensin messenger RNA in the hypothalamus of the obese (ob/ob) mouse. Endocrinology 1993; 132: 1939-1944.
13. Kowalski TJ, Houpt TA, Jahng J et al. Neuropeptide Y overexpression in the preweanling Zucker (fa/fa) rat. Physiology and Behavior 1999; 67: 521-525.
14. Robinson SW, Dinulescu DM & Cone RD. Genetic models of obesity and energy balance in the mouse. Annual Review of Genetics 2000; 34: 687-745.
15. Montague CT, Farooqi IS, Whitehead JP et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387: 903-908.
16. Farooqi IS, Yeo GS, Keogh JM et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. Journal of Clinical Investigation 2000; 106: 271-279.
17. Huszar D, Lynch CA, Fairchild-Huntress V et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997; 88: 131-141.
18. Yaswen L, Diehl N, Brennan MB et al. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nature Medicine 1999; 5: 1066-1070.
19. Erickson JC, Clegg KE & Palmiter RD. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996; 381: 415-418.
20. Ericksson JC, Hollopeter G & Palmiter RD. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science 1996; 274: 1704-1707.
21. Pedrazzini T, Seydoux J, Kunstner P et al. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nature Medicine 1998; 4: 722-726.
22. Kushi A, Sasai H, Koizumi H et al. Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. Proceedings of the National Academy of Sciences of the USA 1998; 95: 15 659-15 664.
23. Naveilhan P, Hassani H, Canals JM et al. Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nature Medicine 1999; 5: 1188-1193.
24. Sainsbury A, Schwarzer C, Couzens M et al. Important role of hypothalamic Y2 receptors in bodyweight regulation revealed in conditional knockout mice. Proceedings of the National Academy of Sciences of the USA 2002: 99: 8938-8943.
25. Marsh DJ, Hollopeter G, Kafer KE et al. Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nature Medicine 1998; 4: 718-721.
26. Qian S, Chen H, Weingarth D et al. Neither agouti-related protein nor neuropeptide Y is critically required for the regulation of energy homeostasis in mice. Molecular and Cell Biology 2002; 22: 5027-5035.
27. Gehlert DR, Beavers LS, Johnson D et al. Expression cloning of a human brain neuropeptide Y Y2 receptor. Molecular Pharmacology 1996; 49: 224-228.
28. Batterham RJ, Cowley MA, Small CJ et al. Gut hormone PYY3-36 physiologically inhibits food intake. Nature 2002; 418: 650-654.
29. Eskay RL, Giraud P, Oliver C et al. Distribution of alpha-melanocyte-stimulating hormone in the rat brain: Evidence, that alpha-MSH-containing cells in the arcuate region send projections to extrahypothalamic areas. Brain Research 1979; 178: 55-67.
30. Ollmann MM, Wilson BD, Yang YK et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein [published erratum appears in Science 1998; 281:1615]. Science 1997; 278: 135-138.
31. Broadwell RD & Brightman MW. Entry of peroxidase into neurons of the central and peripheral nervous systems for extracerebral and cerebral blood. Journal of Comparative Neuroanatomy 1976; 166: 257-283.
32. Elmquist JK, Bjorbaek C, Ahima RS et al. Distributions of leptin receptor mRNA isoforms in the rat brain. Journal of Comparative Neuroanatomy 1998; 395: 535-547.
33. Hisano S, Kagotani Y, Tsuruo Y et al. Localization of glucocorticoid receptor in neuropeptide Y-containing neurons in the arcuate nucleus of the rat hypothalamus. Neuroscience Letters 1988; 95: 13-18.
34. Marks JL, Porte DJ, Stahl WL et al. Localization of insulin receptor mRNA in rat brain by in situ hybridization. Endocrinology 1990; 127: 3234-3236.
35. Broberger C, Landry M, Wong H et al. Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin- and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology 1997; 66: 393-408.
36. Baldock PA, Sainsbury A, Couzens M et al. Hypothalamic Y2 receptors regulate bone formation. Journal of Clinical Investigation 2002; 109: 915-921.
37. Wahlestedt C, Yanaihara N & Hakanson R. Evidence for different pre- and post-junctional receptors for neuropeptide Y and related peptides. Regulatory Peptides 1986; 13: 307-318.
38. Hahn TM, Breininger JF, Baskin DG et al. Coexpression of AGRP and NPY in fasting-activated hypothalamic neurons. Nature Neuroscience 1998; 1: 271-272.
39. Shutter JR, Graham M, Kinsey AC et al. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes & Development 1997; 11: 593-602.
40. Parker RM & Herzog H. Regional distribution of Y-receptor subtype mRNAs in rat brain. European Journal of Neuroscience 1999; 11: 1431-1448.
41. Sim LJ & Joseph SA. Arcuate nucleus projections to brainstem regions which modulate nociception. Journal of Chemical Neuroanatomy 1991; 4: 97-109.
42. Baker RA & Herkenham M. Arcuate nucleus neurons that project to the hypothalamic paraventricular nucleus: Neuropeptidergic identity and consequences of adrenalectomy on mRNA levels in the rat. Journal of Comparative Neuroanatomy 1995; 358: 518-530.
43. Sainsbury A & Herzog H. Inhibitory effects of central neuropeptide Y on the somatotropic and gonadotropic axes in male rats are independent of adrenal hormones. Peptides 2001; 22: 467-471.
44. Broberger C, Johansen J, Johansson C et al. The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proceedings of the National Academy of Sciences of the USA 1998; 95: 15 043-15 048.
45. Li BH, Xu B, Rowland NE et al. c-fos expression in the rat brain following central administration of neuropeptide Y and effects of food consumption. Brain Research 1994; 665: 277-284.
46. Stanley BG, Magdalin W, Seirafi A et al. The perifornical area: The major focus of (a) patchily distributed hypothalamic neuropeptide Y-sensitive feeding system(s). Brain Research 1993; 604: 304-317.
47. Bray GA. The MONA LISA hypothesis. Most obesities known are low in sympathetic activity. In Oomura Y, Tarui, S Inoue S & Shimazu T (eds) Progress in Obesity Research 1990; pp 61-66. London: John Libbey and Company Ltd, 1990.
48. Menendez JA, McGregor IS, Healey PA et al. Metabolic effects of neuropeptide Y injections into the paraventricular nucleus of the hypothalamus. Brain Research 1990; 516: 8-14.
49. Broberger C, Visser TJ, Kuhar MJ et al. Neuropeptide Y innervation and neuropeptide-Y-Y1-receptor-expressing neurons in the paraventricular hypothalamic nucleus of the mouse. Neuroendocrinology 1999; 70: 295-305.
50. Diano S, Naftolin F, Goglia F et al. Segregation of the intra- and extrahypothalamic neuropeptide Y and catecholaminergic inputs on paraventricular neurons, including those producing thyrotropin-releasing hormone. Regulatory Peptides 1998; 75-76: 117-126.
51. Fekete C, Legradi G, Mihaly E et al. Alpha-melanocyte-stimulating hormone is contained in nerve terminals innervating thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus and prevents fasting-induced suppression of prothyrotropin-releasing hormone gene expression. Journal of Neuroscience 2000; 20: 1550-1558.
52. Chen G & Van Den Pol AN. Multiple NPY receptors coexist in pre- and postsynaptic sites: Inhibition of GABA release in isolated self-innervating SCN neurons. Journal of Neuroscience 1996; 16: 7711-7724.
53. Elias CF, Saper CB, Maratos-Flier E et al. Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. Journal of Comparative Neurology 1998; 402: 442-459.
54. Stanley BG, Kyrkouli SE, Lampert S et al. Neuropeptide Y chronically injected into the hypothalamus: A powerful neurochemical inducer of hyperphagia and obesity. Peptides 1986; 7: 1189-1192.
55. Hagan MM, Rushing PA, Pritchard LM et al. Long-term orexigenic effects of AgRP-(83-132) involve mechanisms other than melanocortin receptor blockade. American Journal of Physiology 2000; 279: R47-R52.
56. Kim MS, Rossi M, Abusnana S et al. Hypothalamic localization of the feeding effect of agouti-related peptide and alpha-melanocyte-stimulating hormone. Diabetes 2000; 49: 177-182.
57. Kask A, Pahkla R, Irs A et al. Long-term administration of MC4 receptor antagonist HS014 causes hyperphagia and obesity in rats. Neuroreport 1999; 10: 707-711.
58. Thiele TE, Van Dijk G, Yagaloff KA et al. Central infusion of melanocortin agonist MTII in rats: Assessment of c-Fos expression and taste aversion. American Journal of Physiology 1998; 274: R248-R254.
59. Brown KS, Gentry RM & Rowland NE. Central injection in rats of alpha-melanocyte-stimulating hormone analog: Effects on food intake and brain Fos. Regulatory Peptides 1998; 78: 89-94.
60. Kristensen P, Judge ME, Thim L et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 1998; 393: 72-76.
61. Larsen PJ, Vrang N, Petersen PC et al. Chronic intracerebroventricular administration of recombinant CART(42-89) peptide inhibits and causes weight loss in lean and obese Zucker (fa/fa) rats. Obesity Research 2000; 8: 590-596.
62. Rohner-Jeanrenaud F. A neuroendocrine reappraisal of the dual-centre hypothesis: Its implications for obesity and insulin resistance. International Journal of Obesity 1995; 19: 517-534.
63. Rivest S, Deshaies Y & Richard D. Effects of corticotropin-releasing factor on energy balance in rats are sex dependent. American Journal of Physiology 1989; 257: R1417-R1422.
64. Zarjevski N, Cusin I, Vettor R et al. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 1993; 133: 1753-1758.
65. Small CJ, Kim MS, Stanley SA et al. Effects of chronic central nervous system administration of agouti-related protein in pair-fed animals. Diabetes 2001; 50: 248-254.
66. Cettour-Rose P & Rohner-Jeanrenaud F. The leptin-like effects of 3-d peripheral administration of a melanocortin agonist are more marked in genetically obese Zucker (fa/fa) than in lean rats. Endocrinology 2002; 143: 2277-2283.
67. Fekete C, Kelly J, Mihaly E et al. Neuropeptide Y has a central inhibitory action on the hypothalamic-pituitary-thyroid axis. Endocrinology 2001; 142: 2606-2613.
68. Kim MS, Small CJ, Stanley SA et al. The central melanocortin system affects the hypothalamo-pituitary thyroid axis and may mediate the effect of leptin. Journal of Clinical Investigation 2000; 105: 1005-1011.
69. Legradi G & Lechan RM. Agouti-related protein containing nerve terminals innervate thyrotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Endocrinology 1999; 140: 3643-3652.
70. Legradi G & Lechan RM. The arcuate nucleus is the major source for neuropeptide Y-innervation of thyrotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Endocrinology 1998; 139: 3262-3270.
71. Stanley SA, Small CJ, Murphy KG et al. Actions of cocaine- and amphetamine-regulated transcript (CART) peptide on regulation of appetite and hypothalamo-pituitary axes in vitro and in vivo in male rats. Brain Research 2001; 893: 186-194.
72. Szreder Z, Hori T & Kaizuka Y. Thermoregulatory effect of intracerebral injections of neuropeptide Y in rats at different environmental temperatures. General Pharmacology 1994; 25: 85-91.
73. Currie PJ & Coscina DV. Dissociated feeding and hypothermic effects of neuropeptide Y in the paraventricular and perifornical hypothalamus. Peptides 1995; 16: 599-604.
74. Hwa JJ, Witten MB, Williams P et al. Activation of the NPYY5 receptor regulates both feeding and energy expenditure. American Journal of Physiology 1999; 277: R1428-R1434.
75. Kotz CM, Briggs JE, Grace MK et al. Divergence of the feeding and thermogenic pathways influenced by NPY in the hypothalamic PVn of the rat. American Journal of Physiology 1998; 44: R471-R477.
76. Egawa M, Yoshimatsu H & Bray GA. Neuropeptide Y suppresses sympathetic activity to interscapular brown adipose tissue in rats. American Journal of Physiology 1991; 260: R328-R334.
77. Ste. Marie L, Miura GI, Marsh DJ et al. A metabolic defect promotes obesity in mice lacking melanocortin-4 receptors. Proceedings of the National Academy of Sciences of the USA 2000; 97: 12 339-12 344.
78. Baran K, Preston E, Wilks D et al. Chronic central melanocortin-4 receptor antagonist and central neuropeptide-y infusion in rats produce increased adiposity by divergent pathways. Diabetes 2002; 51: 152-158.
79. Murphy B, Nunes CN, Ronan JJ et al. Centrally administered MTII affects feeding, drinking, temperature, and activity in the Sprague-Dawley rat. Journal of Applied Physiology 2000; 89: 273-282.
80. Hamilton BS & Doods HN. Chronic application of MTII in a rat model of obesity results in sustained weight loss. Obesity Research 2002; 10: 182-187.
81. Wang C, Billington CJ, Levine AS et al. Effect of CART in the hypothalamic paraventricular nucleus on feeding and uncoupling protein gene expression. Neuroreport 2000; 11: 3251-3255.
82. Rohner-Jeanrenaud F, Craft LS, Bridwell J et al. Chronic central infusion of cocaine- and amphetamine-regulated transcript (CART 55-102): Effects on body weight homeostasis in lean and high-fat-fed obese rats. International Journal of Obesity 2002; 26: 143-149.
83. Asakawa A, Inui A, Yuzuriha H et al. Cocaine-amphetamine-regulated transcript influences energy metabolism, anxiety and gastric emptying in mice. Hormone and Metabolic Research 2001; 33: 554-558.
84. Abbott CR, Rossi M, Wren AM et al. Evidence of an orexigenic role for cocaine- and amphetamine-regulated transcript after administration into discrete hypothalamic nuclei. Endocrinology 2001; 142: 3457-3463.
85. Makimura H, Mizuno TM, Roberts J et al. Adrenalectomy reverses obese phenotype and restores hypothalamic melanocortin tone in leptin-deficient ob/ob mice. Diabetes 2000; 49: 1917-1923.
86. Butler AA & Cone RD. Knockout models resulting in the development of obesity. Trends in Genetics 2001; 17: S50-S54.
87. Heilig M, Vecsei L & Widerlov E. Opposite effects of centrally administered neuropeptide Y (NPY) on locomotor activity of spontaneously hypertensive (SH) and normal rats. Acta Physiologica Scandinavica 1989; 137: 243-248.
88. Kimmel HL, Gong W, Vechia SD et al. Intra-ventral tegmental area injection of rat cocaine and amphetamine-regulated transcript peptide 55-102 induces locomotor activity and promotes conditioned place preference. Journal of Pharmacology and Experimental Therapeutics 2000; 294: 784-792.
89. Cusin I, Terrettaz J, Rohner-Jeanrenaud F et al. Hyperinsulinemia increases the amount of GLUT4 mRNA in white adipose tissue and decreases that of muscles: A clue for increased fat depot and insulin resistance. Endocrinology 1990; 127: 3246-3248.
90. Marangou AG, Weber KM, Boston RC et al. Metabolic consequences of prolonged hyperinsulinemia in humans. Evidence for induction of insulin insensitivity. Diabetes 1986; 35: 1383-1389.
91. Pontiroli AE, Alberetto M & Pozza G. Patients with insulinoma show insulin resistance in the absence of arterial hypertension. Diabetologia 1992; 35: 294-295.
92. Assimacopoulos-Jeannet F & Jeanrenaud B. The hormonal and metabolic basis of experimental obesity. Clinics in Endocrinology and Metabolism 1976; 5: 337-365.
93. Standridge M, Alemzadeh R, Zemel M et al. Diazoxide down-regulates leptin and lipid metabolizing enzymes in adipose tissue of Zucker rats. FASEB Journal 2000; 14: 455-460.
94. Sainsbury A, Rohner-Jeanrenaud F, Cusin I et al. Chronic central neuropeptide Y infusion in normal rats - Status of the hypothalamo-pituitary-adrenal axis, and vagal mediation of hyperinsulinaemia. Diabetologia 1997; 40: 1269-1277.
95. Raposinho PD, Castillo E, D'Alleves V et al. Chronic blockade of the melanocortin 4 receptor subtype leads to obesity independently of neuropeptide Y action, with no adverse effects on the gonadotropic and somatotropic axes. Endocrinology 2000; 141: 4419-4427.
96. Yen TT, Gill AM, Frigeri LG et al. Obesity, diabetes and neoplasia in yellow A(vy)/- mice: Ectopic expression of the agouti gene. FASEB Journal 1994; 8: 479-488.
97. Boston BA, Blaydon KM, Varnerin J et al. Independent and additive effects of central POMC and leptin pathways on murine obesity. Science 1997; 278: 1641-1644.
98. Rebuffe-Scrive M, Walsh UA, McEwen B et al. Effect of chronic stress and exogenous glucocorticoids on regional fat distribution and metabolism. Physiology and Behaviour 1992; 52: 583-590.
99. Dallman MF, Strack AM, Akana SF et al. Feast and famine: Critical role of glucocorticoids with insulin in daily energy flow. Frontiers in Neuroendocrinology 1993; 14: 303-347.
100. Green PK, Wilkinson CW & Woods SC. Intraventricular corticosterone increases the rate of body weight gain in underweight adrenalectomized rats. Endocrinology 1992; 130: 269-275.
101. Zakrzewska KE, Cusin I, Stricker-Krongrad A et al. Induction of obesity and hyperleptinemia by central glucocorticoid infusion in the rat. Diabetes 1999; 48: 365-370.
102. McMahon M, Gerich J & Rizza R. Effects of glucocorticoids on carbohydrate metabolism. Diabetes/Metabolism Reviews 1988; 4: 17-30.
103. Sainsbury A, Wilks D & Cooney GJ. Central but not peripheral glucocorticoid infusion in adrenalectomized male rats increases basal and substrate-induced insulinemia via a parasympathetic pathway. Obesity Research 2001; 9: 274-281.
104. McDonald JK & Koenig JI. Neuropeptide Y actions on reproductive and endocrine functions. In Colmers WF & Wahlestedt C (eds) The Biology of Neuropeptide Y and Related Peptides, pp 419-456. New Jersey: Humana Press Inc, 1993.